Last reviewed · How we verify
Delayed administration of convalescent plasma
Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.
Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease. Used for COVID-19 (delayed administration in hospitalized patients).
At a glance
| Generic name | Delayed administration of convalescent plasma |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Immunoglobulin/passive immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Convalescent plasma is collected from patients who have recovered from infection and contains pathogen-specific antibodies and other immune mediators. When administered to acutely ill patients, these antibodies provide immediate passive immunity to neutralize the pathogen and modulate the immune response. Delayed administration refers to timing the infusion after initial disease progression rather than early in infection.
Approved indications
- COVID-19 (delayed administration in hospitalized patients)
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reactions
- Transfusion-associated circulatory overload (TACO)
- Fever
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia (PHASE2)
- Convalescent Plasma in Pediatric COVID-19 (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: